CERE - Cerevel Therapeutics Holdings, Inc. Stock Price, Fair Value and News

$44.960.00 (0.00%)

Market Closed as of 01 Aug 2024, 04:00 pm ET

CERE Stock Valuation Analysis

Valuation

Max Portfolio %

CERE Price Action

CERE RSI Chart

CERE Stock Valuation Analysis

Valuation

Max Portfolio %

CERE Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CERE Fundamentals

CERE Revenue

CERE Earnings

CERE Profitability

CERE Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2021	35.0K	40.0K	52.0K	-
2020	1.2M	888.0K	556.0K	224.0K
2019	-	-	-	1.6M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Ronald C. Renaud Jr., M.B.A., MBA
WEBSITE	cerevel.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	322